XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN) is a clinical-stage biopharmaceutical company that completed its business combination with B. Riley Principal 150 Merger Corp., a blank-check company sponsored by B. Riley Principal Capital, which conducted its IPO in 2018. The company filed a quarterly report on Form 10-Q with the SEC on August 15, 2019, reflecting its status as a reporting public company following the de-SPAC transaction. Xynomic is focused on the development of oncology therapeutics, positioning it within the life sciences and biopharma sector. Investors and researchers tracking XYN can sign up at SpacDesk for full filing history, deal timelines, and sponsor data.